(Bloomberg) — Mounting cases of bird flu in humans is luring the day trading crowd to snap up stock in vaccine developers. It’s a familiar setup for industry veterans who have witnessed past trading frenzies at the first signs of an outbreak.
Most Read from Bloomberg
Shares of CureVac NV, which has a bird-flu vaccine in early-stage testing, jumped 15% Wednesday as concerns grow over a potential outbreak of bird flu in humans following reports of a new case in Australia. Novavax Inc. — which recently touted its plans to explore an avian flu vaccine — gained for the third day closing at its highest level since December 2022.
Shares of Moderna Inc. rose 2.9% in afterhours trading while Pfizer Inc.’s gained 1.4% following a report that the companies are in talks with the US government about the development of vaccines for bird flu. Moderna and fellow Covid shotmaker BioNTech SE…
